Healthcare providers and insurers were busy implementing healthcare reform in 2014, millions of uninsured Americans gained coverage, and healthcare spending growth remained modest even as partisan warfare over the Patient Protection and Affordable Care Act continued in full force.
The Food and Drug Administration on Friday approved Viekira Pak, a combination of pills that becomes the fourth treatment the agency has approved in the past year to treat hepatitis C.
Actuaries say it's getting increasingly difficult to advise states on sound rates for Medicaid managed-care plans because high-priced specialty drugs like Sovaldi continue to hit the market at a rapid clip.
A not-for-profit organization created and funded by the healthcare reform law plans to spend up to $50 million on comparative effectiveness research for hepatitis C treatments just as the government is set to approve the third drug in a new breed of treatment regimens.
Gilead Sciences' eye-popping $1,000-a-pill cost for its hepatitis C drug Sovaldi is illegal price-gouging with the potential to bankrupt parts of the healthcare industry, according to a lawsuit filed in federal court Tuesday.
That's the updated estimate of the cost to develop a new drug from the Tufts Center for the Study of Drug Development. Anyone with even a rudimentary understanding of corporate accounting knows the claim is bogus.
Hospitals traditionally have been less concerned with drug costs in the outpatient setting. But that's changing with the move away from fee-for-service payments and a broader push to improve value for patients.
Drugmaker Gilead Sciences again reported record growth as sales of its hepatitis C blockbuster Sovaldi topped $2.8 billion in the third quarter of the year.
Medicaid managed-care plan operators are looking for a way to pay for high-priced specialty drugs such as Sovaldi and Harvoni, the $1,000-per-pill treatments approved by the Food and Drug Administration to treat hepatitis C.
A second potential blockbuster drug from Gilead Sciences to treat hepatitis C has been approved by the FDA. But at a cost of nearly $100,000 for a full course of treatment, it is certain to spark further debate over the pricing of specialty drugs.
A second potential blockbuster drug manufactured by Gilead Sciences to treat hepatitis C has been approved by the FDA. But at a cost of nearly $100,000 for a full course of treatment, the drug is certain to spark further debate over the pricing of specialty drugs
Sovaldi-maker Gilead Sciences is making state Medicaid directors an offer they feel they must refuse, said Matt Salo, executive director of the National Association of Medicaid Directors, who spoke Wednesday at a Medicaid conference sponsored by America's Health Insurance Plans.